Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMY ) 11.45 -0.42 (-3.54%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Astellas Pharma Inc < Previous 1 2 3 Next > 'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover February 27, 2023 The potential deal follows rumors last year that Merck could buy Seagen. Via Investor's Business Daily Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them February 13, 2023 Super Bowl LVII aired Sunday Feb. 12, 2023 and featured dozens of commercials advertising products and showcasing new movies and television shows. The commercials also featured many celebrity cameos... Via Benzinga Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts January 31, 2023 Via Benzinga Astellas' Menopause Drug Under FDA Review August 18, 2022 Via Benzinga Sutro Biopharma Stock Surges On Cancer Treatment Pact June 28, 2022 Via Benzinga Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold June 27, 2022 Via Benzinga Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering January 24, 2023 Via Benzinga What Is Going on With Taysha Gene (TSHA) Stock Today? October 25, 2022 Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases. Via InvestorPlace Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs October 25, 2022 Via Benzinga Seagen Shares Jump On Positive Data From Urothelial Cancer Trial July 26, 2022 Via Benzinga 7 Best Biotech Stocks to Buy in July 2022 July 08, 2022 The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. Via InvestorPlace Astellas' Menopause Drug Suffers Setback After Failed Asian Trial March 15, 2022 Via Benzinga The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies June 27, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies May 09, 2022 Via Benzinga Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer April 13, 2022 The Via Benzinga Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing March 07, 2022 Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor... Via Benzinga Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients February 15, 2022 Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (... Via Benzinga Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact December 02, 2021 Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... Via Benzinga 4 No-Brainer Pharmaceutical Stocks to Buy in October September 27, 2021 While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical... Via Talk Markets Exposures COVID-19 Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan September 27, 2021 Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically... Via Benzinga Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold September 14, 2021 Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics... Via Benzinga Exposures Product Safety See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial September 01, 2021 Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in... Via Benzinga The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout September 14, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... Via Benzinga Exposures COVID-19 After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat August 20, 2021 The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... Via Benzinga Exposures Product Safety Here's What Recent News From the FDA Means for AstraZeneca August 20, 2021 Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. Via The Motley Fool Exposures Product Safety The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering September 01, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... Via Benzinga FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial August 11, 2021 The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease... Via Benzinga Exposures Product Safety The IPO Recap – Party Is Everything But Over July 28, 2021 Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled IPOs, marking the fifth week in 2021 with... Via Benzinga Topics Initial Public Offering Exposures Securities Market The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data August 20, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... Via Benzinga Exposures COVID-19 Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer July 12, 2021 The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat... Via Benzinga Exposures Product Safety < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.